Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: European Journal of Cancer, 151, S. 3-13
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2021
- Ereignis
-
Veröffentlichung
- (wer)
-
Elsevier BV
- (wann)
-
2021
- Urheber
-
Riedl, Jakob M.
Posch, Florian
Horvath, Lena
Gantschnigg, Antonia
Renneberg, Felix
Schwarzenbacher, Esther
Moik, Florian
Barth, Dominik A.
Rossmann, Christopher H.
Stotz, Michael
Schaberl-Moser, Renate
Pichler, Martin
Stöger, Herbert
Greil, Richard
Djanani, Angela
Schlick, Konstantin
Gerger, Armin
- DOI
-
10.1016/j.ejca.2021.03.040
- URN
-
urn:nbn:de:bvb:384-opus4-1016393
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Riedl, Jakob M.
- Posch, Florian
- Horvath, Lena
- Gantschnigg, Antonia
- Renneberg, Felix
- Schwarzenbacher, Esther
- Moik, Florian
- Barth, Dominik A.
- Rossmann, Christopher H.
- Stotz, Michael
- Schaberl-Moser, Renate
- Pichler, Martin
- Stöger, Herbert
- Greil, Richard
- Djanani, Angela
- Schlick, Konstantin
- Gerger, Armin
- Universität Augsburg
- Elsevier BV
Entstanden
- 2021
Ähnliche Objekte (12)
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Best of ASCO 2022: bladder cancer
Pankreaskarzinom nab-Paclitaxel
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Breast cancer nab-Paclitaxel
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Best of ASCO 2022: bladder cancer
Pankreaskarzinom nab-Paclitaxel
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Breast cancer nab-Paclitaxel
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Best of ASCO 2022: bladder cancer
Pankreaskarzinom nab-Paclitaxel
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer
Breast cancer nab-Paclitaxel
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients